The current study was aimed to develop and validate a simple and sensitive method to quantify valganciclovir and its metabolite ganciclovir in human plasma using valganciclovir-D5, ganciclovir-D5 as internal standards for pharmacokinetic analyses. The method exhibited highly sensitive ranges 2-805 ng/ml for valganciclovir and 40-12000 ng/ml for ganciclovir. The analytes were extracted from plasma using solid phase extraction employing mixed-mode cation exchange cartridges. Valganciclovir and ganciclovir were separated using Agilent XDB-Phenyl column with a mobile phase consisting 35:65 ratio of 10 mM ammonium acetate in 0.3 % formic acid and acetonitrile at 0.60 ml/min flow rate with 2.50 min run time. The validated parameters were within the acceptance criteria as per the regulatory guidelines and the validated calibration curve ranges to both analytes have r value >0.99 with above 90 % recovery. The validated method was successfully used to study pharmacokinetics of orally administered valganciclovir (900 mg) in healthy male volunteers. The pharmacokinetic parameters were, C max 300 ng/ml for valganciclovir and 6000 ng/ml for ganciclovir, and t max 0.50 h for valganciclovir and 1.00 h for ganciclovir.
Research Paper
The discovery and development of new drugs involved many vital processes such as drug identification, isolation, synthesis and analysis [1] . The analysis part is most important and very difficult for new drugs because, the results indicate their purity, quantification and interpretation of these data play key role in identification and estimation of their pharmacological activity [2, 3] . In last few decades, several new diseases have emerged like Ebola and some diseases have become untreatable [4, 5] . This situation prompted the researchers to discover new drugs and new analytical methods to identify accurately with reliable certainty [6] . In the present-day viral infections fall under this situation, because these affect epidemically and pandemically the population around the world [7, 8] .
Valganciclovir (VAL) is one of the antiviral drug to treat the cytomegalovirus (CMV) infections in acquired immune deficiency syndrome (AIDS) patients for retinitis and in organ transplantation condition to prevent CMV infections [9, 10] . VAL is a prodrug for ganciclovir (GAN), which is an analogue for 2'-deoxyguanosine and the deoxyribonucleic acid (DNA) synthesis is terminated by inhibiting the DNA polymerase enzyme in CMV by replacing the 2' deoxyguanosine triphosphate [11] [12] [13] [14] . The World Health Organization (WHO) added VAL as essential medicine as an effective and safe medicine needed for human wealth [15] . Recently, US FDA approved the manufacturing of generic VAL but the available analytical methods for VAL are not suitable to quantify in different biological matrices. There are some early reports on bio-analytical methods for VAL, GAN but, they are old, were analysed with nondeuterated drugs as internal standards (IS) and are not sensitive [16] [17] [18] [19] . The high accuracy results are very important in quantification of drugs using IS through liquid chromatography with tandem mass spectrometry (LC-MS-MS), use of stable isotope labelled ISs usage provides the accurate results and reduces the variations in MS [20, 21] . So, the current study was aimed to develop new bio-analytical method with deuterated drugs as IS for VAL and GAN in human plasma and its validation as per regulatory guidelines (US FDA).
MATERIALS AND METHODS
The solvents used in the current investigation were LC-MS grade (J.T. Baker, USA). Analytical grade formic acid (98-100 %) was from Merck (Mumbai, India). Standard VAL, GAN, GAN D5 were procured from Vivan Life Sciences (Mumbai, India) and VAL D5 was procured from Clear Synth Labs (Mumbai, India). The human plasma with K2 EDTA as anticoagulant was obtained from Deccan Pathological Laboratory (Hyderabad, India). The LC-MS-MS used was equipped with an LC system from Shimadzu (Japan) and API-4000 MS-MS from Sciex (USA); XDB Phenyl 4.6×75 mm (Make-Agilent) column was used.
Standard and internal standard stock solution:
VAL stock solution (1 mg/ml) was prepared in methanol and GAN, GAN D5, VAL D5 were also prepared as 1 mg/ml solutions in dimethyl sulphoxide. These stock solutions were used for further dilutions with 50 % acetonitrile (ACN) in HPLC grade water (diluent) to prepare calibration curve and quality control (QC) samples. The calibration curve points were ten nonzero concentrations with range 2.04-805.35 ng/ml for VAL and 40.41-12097.57 ng/ml for GAN and QCs were 2.05 ng/ml (lower limit of quantification quality control, LLOQ QC), 6.01 ng/ml (lower quality control, LQC), 125.28 ng/ml (middle quality control 1, MQC1), 377.35 ng/ml (middle quality control 2, MQC2), and 566.56 ng/ml (high quality control, HQC) for VAL and 40.43 ng/ml (LLOQ QC), 121.04 ng/ml (LQC), 1806.56 ng/ml (MQC1), 6021.89 ng/ml (MQC2), and 9041.88 ng/ml (HQC) for GAN as final concentrations in blank plasma spiked as 5 % from 20 times working concentrations prepared with diluent using standard stock solutions. Dilution integrity (DI) samples were prepared by spiking 3.10 times (2495.07 ng/ml of VAL and 3.16 times of 38205.11 ng/ml of GAN) of the highest standard concentration. These spiked samples were stored at -70° and 12 sets of LQC and HQC at -20° for further validation study.
LC-MS/MS method optimization:
The separation and quantification of VAL and GAN were carried out using LC-MS/MS with positive and negative ionization modes, finally fixed to positive ion mode with different mass optimization parameters such as the curtain gas (CUR) and collision energy (CE) for VAL and GAN. The final optimized parameters for mass spectrometry are shown in Table 1 . Separation of the two analyte from the same sample is always difficult using LC at different concentrations of analytes but VAL and GAN were separated successfully with good response even at low concentrations. The optimized chromatographic conditions are listed in Table 2 .
Sample preparation:
The solid phase extraction (SPE) method was used to extract the drugs from plasma samples. About 250 µl of the plasma sample was pipetted into pre-labelled RIA vials, which contained 25 µl of ISs dilution (from working concentrations, 5000 ng/ml of VAL D5 and 10000 ng/ml of GAN D5), except in blank plasma samples where 25 µl diluent was added and then samples were vortexed. Then, 200 µl of 2 % orthophosphoric acid (OPA) buffer was added and vortexed. The sample mixture was loaded onto Strata™-X-C, 33 µ strong cation cartridges (30 mg/ml), pre-conditioned with 1.0 ml methanol, followed by 1.0 ml water. After applying maximum pressure, the extraction cartridge was washed with 1.0 ml of 2 % OPA buffer and followed by 1.0 ml of 5 % methanol in water. Then, the sample was eluted with 1.0 ml of 5 % ammonia in methanol. The samples were the evaporated to dryness at 50° in turbo evaporator under nitrogen gas and reconstituted the residue with 500 µl of mobile phase and vortexed. The reconstituted samples were centrifuged at 4000 rpm at 4° for 5 min and transferred into vials and loaded on to the auto sampler.
Method validation:
The developed method for quantification of VAL and GAN was validated as per USFDA guidelines [22] . The method validation included determination of sensitivity, selectivity, matrix effect (ME), linearity, accuracy, precision, recovery, DI, run size evaluation (RSE) and stability (room temperature, RT (20±5°) stock solution stability, refrigerated stock solution stability at 2-8°, freeze-thaw stability, bench top stability, short-term plasma samples stability at 20±5°, wet extract stability at 20±5º and auto sampler stability (AS).
The sensitivity was measured to check back noise by spiking 6 LLOQ QC samples. Ten lots of blank plasma samples including lipemic and haemolytic were used for selectivity and ME was checked. Linearity was checked with in the concentration range of 2 Stability is very important in quantification of any drugs in aqueous or in different biological matrices. Stability studies for VAL and GAN in the developed method were carried out at different conditions; re-injection stability was checked for retention of already injected samples stability in auto sampler, AS was checked for the retention of processed samples, which were kept in auto sampler for analysis, wet extract stability was carried to know the stability of processed samples at RT, bench-top stability was carried to express the stability of drugs in spiked plasma after thawing, shortterm stability was carried to know the stability of drugs in spiked plasma at -20° because usually spiked plasma samples were stored at -70°, whole blood stability was studied to check the stability of drug in blood at RT and freeze-thaw stability was done to provide the number of freeze-thaw cycles for processing of spiked plasma.
Data processing:
Analyst 1.6.3 software was used for the chromatograms were acquired and processed by peak area ratio. The concentration of the unknown was calculated from the following Eqn. using regression analysis of spiked standard with the reciprocal of the square of ratio of the drug concentration to internal standard concentration as a weighting factor (1/concentration ratio)×2, y=mx+c, where, y is peak area ratio of VAL and GAN to IS; m is the slope of the calibration curve, x is the concentration of VAL and GAN (ng/ml), and c is y-axis intercept of the calibration curve.
Clinical application:
The developed and validated method was applied in a clinical study on 6 healthy volunteers for 
RESULTS AND DISCUSSION
Method development involved the detection of ions of VAL, GAN and their ISs using mass spectrometry, separation using LC and extraction of VAL and GAN from plasma using SPE. Before finalizing the above mentioned mass optimized parameters ( 
Fig. 2: MRM spectra of valganciclovir and ganciclovir of blank plasma samples A. blank-valganciclovir, B. blank-valganciclovir D5, C. blankganciclovir and D. blank-ganciclovir D5
limits as per regulatory guidelines for VAL and GAN ( Table 5 ).
The results of the DI at 25:75 of VAL and GAN (2495.07 ng/ml of VAL and 38205.11 ng/ml of GAN) were analysed as 6 replicates, which were found to be within the acceptance criteria with precision (1.27) and accuracy (100.08 %) to VAL and precision (1.04) and accuracy (108.05 %) to GAN and the processed sample have nominal concentration within ±15 %.
Stability of VAL and GAN was studied under diverse conditions and the results are summarized in Table 6 . VAL and GAN stock solutions were stable at RT for 21 h and spiking samples (bench-top stability) stable at RT for 10 h. The spiked storage samples at -70° were found to be stable after 4 freeze-thaw cycles. VAL and GAN were stable after the processing i.e. wet extract stability at RT and AS at 5° were 51 h and 63 h, respectively. The re-injection stability for the processed sample was 41 h. All the tested conditions for VAL and GAN stability of their CCs and QCs were within the acceptance criteria (±15 % of their nominal concentration). were analysed as single batch. All the processed samples were within the acceptance criteria as their nominal concentration was ±15 % at each QC level.
The validated method was successfully applied to a clinical study on healthy human volunteers (n=6) with 50 mg/ml of 900 mg oral solution dosage at fasting condition. The mean results of drug concentration versus time are shown in fig 5a (VAL) and 5b (GAN) of GAN was about 5000 ng/ml at T max 1.00 h. The pharmacokinetic parameters were summarized in Table 7 . After the study sample analysis, ISR was also carried out because it is important to know the reproducibility of concentration vs. time and is necessary for the approval of drugs by USFDA. The performed ISR analysis samples were within the acceptance (<20 %) variation from their initial values (Table 8) .
Bioanalysis plays a key role in the drug discovery process by providing reliable pharmacokinetic parameters by estimating the test drug concentrations in biological matrices like blood, plasma, and urine [23, 24] . Currently the situation of emerging and resistant diseases is prompting the researchers to discover lead drug molecules with broad therapeutic values. These discoveries simultaneously require reliable analytical methods with rapid analysis and accuracy. HIV is most mortality causing disease in the world from mid-20th century and researchers developed few drugs to control the disease and its side effects but till now there is no drug to cure HIV/AIDS. VAL is one of the antiviral drugs effective against CMV infections in HIV/AIDS patients and also used to control CMV infections in organ transplantation condition. VAL is a prodrug of GAN, which inhibits the chain elongation of viral replication [13] . Since the WHO declared VAL as an essential medicine [14] and that VAL received generic approval, it became very essential that fast and reliable methods are available to quantify VAL and GAN in different biological matrices from generic formulations under development to get marketing approval. In an attempt to fill this gap, the current study was taken up to develop a simple and rugged method to evaluate VAL and GAN simultaneously in human plasma, validate it as per USFDA guidelines and to apply this method to determine pharmacokinetic parameters of VAL and GAN.
The developed and validated method is the first method which used deuterated compounds as ISs. Because ISs are very important to obtain high accuracy when LC is coupled with a mass detector and stable isotopelabelled (stable ISs) drugs as ISs help to find possible ME [25] . The earlier reported methods for VAL and GAN used non-isotope drugs as ISs [17, 18] . The validated method is found to have very high sensitivity, since the method facilitated quantification of VAL and GAN at 2 ng/ml and 40 ng/ml, respectively with high recovery (>90 %) and low runtime making this method an economic and easy to run method compared to other reported methods [16, 19] . The developed and validated method using deuterated IS was found reliable and could be successfully applied to a clinical study to estimate VAL and GAN in human plasma samples quite effectively.
